Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 440 participants.

Also called NCT03072121

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 440 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03072121
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03072121. Randomized; double masking; primary purpose treatment. Start 2017-06 (anticipated); primary completion 2018-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization
Intervention (Drug)
Shexiang Baoxin pill
Intervention (Drug)
SBP placebo
Intervention (Drug)
Aspirin Enteric-coated Tablets
Intervention (Drug)
Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Intervention (Drug)
Atorvastatin Calcium
Intervention (Drug)
Isosorbide Mononitrate Tab 20 MG
Intervention (Drug)
Metoprolol Tartrate Tab 25 MG
Intervention (Drug)
Trimetazidine Dihydrochloride Tablets
Lead sponsor
Jun Li (class: other)
Collaborator
Shanghai Hutchison Pharmaceuticals Limited (class: industry)

Record details

Record id
cardio:ct-nct03072121
Content hash
0ab60d2d2e32bf9447f354ae7f85a619c75387bf36d6ab9e609ccc40f01a898c